HK1206251A1 - Human anti-cd27 antibodies, methods and uses cd27 - Google Patents
Human anti-cd27 antibodies, methods and uses cd27Info
- Publication number
- HK1206251A1 HK1206251A1 HK15106811.7A HK15106811A HK1206251A1 HK 1206251 A1 HK1206251 A1 HK 1206251A1 HK 15106811 A HK15106811 A HK 15106811A HK 1206251 A1 HK1206251 A1 HK 1206251A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- methods
- human anti
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261611332P | 2012-03-15 | 2012-03-15 | |
PCT/US2013/031314 WO2013138586A1 (en) | 2012-03-15 | 2013-03-14 | Human anti-cd27 antibodies, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206251A1 true HK1206251A1 (en) | 2016-01-08 |
Family
ID=49157853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106811.7A HK1206251A1 (en) | 2012-03-15 | 2015-07-17 | Human anti-cd27 antibodies, methods and uses cd27 |
Country Status (28)
Country | Link |
---|---|
US (6) | US9102737B2 (ja) |
EP (1) | EP2825200A4 (ja) |
JP (1) | JP6487839B2 (ja) |
KR (1) | KR102153374B1 (ja) |
CN (1) | CN104284678B (ja) |
AR (1) | AR090356A1 (ja) |
AU (1) | AU2013232087B2 (ja) |
BR (2) | BR112014022812A2 (ja) |
CA (1) | CA2867299C (ja) |
CL (1) | CL2014002416A1 (ja) |
CO (1) | CO7071095A2 (ja) |
CR (1) | CR20140415A (ja) |
EA (1) | EA030828B1 (ja) |
EC (1) | ECSP14018641A (ja) |
GT (1) | GT201400193A (ja) |
HK (1) | HK1206251A1 (ja) |
JO (1) | JO3787B1 (ja) |
MX (1) | MX363946B (ja) |
MY (1) | MY175224A (ja) |
NZ (1) | NZ629697A (ja) |
PE (1) | PE20142242A1 (ja) |
PH (2) | PH12014502011B1 (ja) |
SG (2) | SG11201405437QA (ja) |
TW (2) | TWI576354B (ja) |
UA (1) | UA121844C2 (ja) |
UY (1) | UY34680A (ja) |
WO (1) | WO2013138586A1 (ja) |
ZA (2) | ZA201407440B (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 cd27에 결합하는 항체 및 이의 용도 |
CN103596979B (zh) | 2011-03-16 | 2018-01-26 | 阿尔金-X有限公司 | 针对cd70的抗体 |
WO2014140374A2 (en) * | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Monovalent cd27 antibodies |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
FR3025517B1 (fr) * | 2014-09-10 | 2016-12-23 | Repropharm | Ligands potentialisants de la bioactivite des gonadotrophines |
WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
EA037882B1 (ru) | 2015-09-30 | 2021-05-31 | Янссен Байотек, Инк. | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
CA3002602C (en) * | 2015-10-23 | 2021-11-02 | Apogenix Ag | Single-chain cd27-receptor agonist proteins |
TW201736399A (zh) | 2015-12-31 | 2017-10-16 | 財團法人生物技術開發中心 | 抗vegfr抗體及其應用 |
CN109071665B (zh) | 2016-04-18 | 2022-11-01 | 塞德斯医疗公司 | 结合人cd40的激动性抗体及其用途 |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
TW201813979A (zh) * | 2016-09-29 | 2018-04-16 | 江蘇恆瑞醫藥股份有限公司 | 抗cd27抗體、其抗原結合片段及其醫藥用途 |
US11242402B2 (en) * | 2016-12-23 | 2022-02-08 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
KR20200005596A (ko) | 2017-05-12 | 2020-01-15 | 크리스퍼 테라퓨틱스 아게 | 세포를 엔지니어링하기 위한 물질 및 방법, 및 면역-종양학에서의 그의 용도 |
EP3648757A4 (en) * | 2017-07-03 | 2020-11-25 | Development Center for Biotechnology | ANTI-VEGFR ANTIBODIES AND USES THEREOF |
WO2019037131A1 (zh) * | 2017-08-25 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 一种cd27真核表达载体的构建及其高表达细胞株的制备 |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
US11560421B2 (en) * | 2018-02-09 | 2023-01-24 | Osaka University | Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein |
US20210009706A1 (en) * | 2018-03-28 | 2021-01-14 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof |
US20210155703A1 (en) * | 2018-04-04 | 2021-05-27 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
US11795230B2 (en) | 2018-04-13 | 2023-10-24 | Dingfu Biotarget Co., Ltd. | Anti-CD27 antibodies and use thereof |
JP7466459B2 (ja) * | 2018-04-17 | 2024-04-12 | セルデックス セラピューティクス インコーポレイテッド | 抗cd27および抗pd-l1抗体ならびに二重特異性構築物 |
EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70組合治療 |
US20220144961A1 (en) * | 2019-03-11 | 2022-05-12 | Xyence Therapeutics, Inc. | Cd27-binding antibodies and uses thereof |
MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
TW202112812A (zh) * | 2019-05-24 | 2021-04-01 | 香港商安立璽榮生醫(香港)有限公司 | Csf1r抗體、il10融合蛋白及其用途 |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
CN112646029B (zh) * | 2020-12-30 | 2022-07-29 | 深圳清华大学研究院 | 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒 |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CN113444178B (zh) * | 2021-06-17 | 2022-12-02 | 南京蓝盾生物科技有限公司 | 抗cd70内化的抗体、抗体偶联物及其应用 |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
CA2399388A1 (en) | 2000-02-11 | 2001-08-16 | Michael J. Lenardo | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
US6982361B1 (en) | 2000-02-25 | 2006-01-03 | The Regents Of The University Of California | Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
EP1436329A4 (en) | 2001-09-20 | 2005-04-27 | Alexion Pharma Inc | ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES |
WO2003068268A2 (en) | 2002-02-14 | 2003-08-21 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
CA2516128A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
BRPI0611220A2 (pt) | 2005-06-02 | 2010-08-24 | Astrazeneca Ab | anticorpos direcionados para cd20 e usos dos mesmos |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
EP2090320A1 (en) | 2008-02-15 | 2009-08-19 | Helmholtz-Zentrum für Infektionsforschung GmbH | Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof |
US9023999B2 (en) * | 2008-06-30 | 2015-05-05 | Kyowa Hakko Kirin Co., Ltd | Anti-CD27 antibody |
KR101773216B1 (ko) * | 2009-12-29 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 항 cd27 항체 |
KR101958753B1 (ko) * | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 cd27에 결합하는 항체 및 이의 용도 |
EP2591001B1 (en) * | 2010-07-09 | 2021-11-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to cd27 |
-
2013
- 2013-03-14 MY MYPI2014702561A patent/MY175224A/en unknown
- 2013-03-14 WO PCT/US2013/031314 patent/WO2013138586A1/en active Application Filing
- 2013-03-14 EA EA201491700A patent/EA030828B1/ru unknown
- 2013-03-14 JP JP2015500608A patent/JP6487839B2/ja active Active
- 2013-03-14 NZ NZ629697A patent/NZ629697A/en unknown
- 2013-03-14 AU AU2013232087A patent/AU2013232087B2/en active Active
- 2013-03-14 PE PE2014001420A patent/PE20142242A1/es active IP Right Grant
- 2013-03-14 JO JOP/2013/0072A patent/JO3787B1/ar active
- 2013-03-14 BR BR112014022812A patent/BR112014022812A2/pt not_active Application Discontinuation
- 2013-03-14 CN CN201380025446.3A patent/CN104284678B/zh active Active
- 2013-03-14 KR KR1020147028682A patent/KR102153374B1/ko active IP Right Grant
- 2013-03-14 MX MX2014011100A patent/MX363946B/es active IP Right Grant
- 2013-03-14 EP EP13761537.3A patent/EP2825200A4/en active Pending
- 2013-03-14 UA UAA201411147A patent/UA121844C2/uk unknown
- 2013-03-14 SG SG11201405437QA patent/SG11201405437QA/en unknown
- 2013-03-14 BR BR122020002414-3A patent/BR122020002414B1/pt active IP Right Grant
- 2013-03-14 SG SG10201710574UA patent/SG10201710574UA/en unknown
- 2013-03-14 CA CA2867299A patent/CA2867299C/en active Active
- 2013-03-15 US US13/835,518 patent/US9102737B2/en active Active
- 2013-03-15 AR ARP130100851A patent/AR090356A1/es unknown
- 2013-03-15 UY UY0001034680A patent/UY34680A/es not_active Application Discontinuation
- 2013-03-15 TW TW102109158A patent/TWI576354B/zh active
- 2013-03-15 TW TW106102009A patent/TW201730214A/zh unknown
-
2014
- 2014-09-09 CR CR20140415A patent/CR20140415A/es unknown
- 2014-09-09 PH PH12014502011A patent/PH12014502011B1/en unknown
- 2014-09-12 GT GT201400193A patent/GT201400193A/es unknown
- 2014-09-12 CL CL2014002416A patent/CL2014002416A1/es unknown
- 2014-09-12 CO CO14202427A patent/CO7071095A2/es unknown
- 2014-09-12 EC ECIEPI201418641A patent/ECSP14018641A/es unknown
- 2014-10-14 ZA ZA2014/07440A patent/ZA201407440B/en unknown
-
2015
- 2015-02-06 ZA ZA2015/00887A patent/ZA201500887B/en unknown
- 2015-07-02 US US14/790,144 patent/US9683046B2/en active Active
- 2015-07-17 HK HK15106811.7A patent/HK1206251A1/xx unknown
-
2017
- 2017-05-16 US US15/596,609 patent/US10301392B2/en active Active
- 2017-10-19 PH PH12017501908A patent/PH12017501908B1/en unknown
-
2019
- 2019-04-12 US US16/382,645 patent/US10689453B2/en active Active
-
2020
- 2020-05-19 US US16/878,209 patent/US11732050B2/en active Active
-
2023
- 2023-06-29 US US18/216,074 patent/US20240141055A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206251A1 (en) | Human anti-cd27 antibodies, methods and uses cd27 | |
ZA201407927B (en) | Anti-egfr antibodies and uses thereof | |
HK1207092A1 (en) | Anti-hla-b27 antibodies and uses thereof -hla-b27 | |
HRP20190358T1 (hr) | Antitijela protiv asic1 i njihova primjena | |
EP2822592A4 (en) | SPECIFIC TGF-1 ANTIBODIES AND METHODS AND USES THEREOF | |
ZA201500457B (en) | Anti-kit antibodies and uses thereof | |
GB201115529D0 (en) | Antibodies, uses and methods | |
GB201115280D0 (en) | Antibodies, uses and methods | |
HK1213455A1 (zh) | 醫療用緊固件 | |
HK1210913A1 (en) | Particles, methods and uses thereof | |
HK1205523A1 (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1) | |
GB201223330D0 (en) | Products, methods and uses | |
EP2813495A4 (en) | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF | |
AU343512S (en) | Human model | |
EP2837624A4 (en) | 4-SUBSTITUTE-2-HYDROXYLMORPHOLIN-3-ON AND METHOD OF MANUFACTURING THEREOF | |
EP2900693A4 (en) | ADCC-mediating antibodies, combinations and uses thereof | |
GB201208372D0 (en) | Antibodies and uses thereof |